Form 4 ANAPTYSBIO, INC For: Oct 01 Filed by: RENTON HOLLINGS

Fri, 02 Oct 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20261002/27143762.html

Form 144 ANAPTYSBIO, INC Filed by: RENTON HOLLINGS

Thu, 01 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261001/27135967.html

AnaptysBio (ANAB) PT Lowered to $60 at JPMorgan

Wed, 30 Sep 2026 09:09:29 -0400

JPMorgan analyst Anupam Rama lowered the price target on AnaptysBio (NASDAQ: ANAB) to $60.00 (from $70.00) while maintaining a Overweight rating.

AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c

Tue, 22 Sep 2026 07:54:33 -0400

AnaptysBio, Inc. (NASDAQ: ANAB) reported Q2 EPS of $5.11, $5.24 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $27.5 million versus the consensus estimate of $20.22 million.

For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.

H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)

Tue, 22 Sep 2026 07:36:55 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $95.00 price target on AnaptysBio (NASDAQ: ANAB).

The analyst commented: "Yesterday after the close, Anaptys reported 2Q26 financial results. Jemperli remains the primary value driver, with global net sales of $331M in 2Q26, up 26% YoY, and $644M during 1H26, up 34% YoY. Anaptys continues to expect >$390M in annualized Jemperli royalties payable to the company as early as 2029 based on GSK's (GSK; not rated) peak monotherapy sales guidance of >$2.7B. Other updates include: 1) Sagard paydown. Anaptys estimates Sagard had accrued approximately $301M of royalties and sales milestones through

Form 10-KT ANAPTYSBIO, INC For: Jun 30

Mon, 21 Sep 2026 16:24:00 -0400

http://archive.fast-edgar.com/20260921/AF2VL22FZZ2RATZU22ZM2ZYSIVGGZZ22Z28Q

Filed on: September 21, 2026

Form 8-K ANAPTYSBIO, INC For: Sep 21

Mon, 21 Sep 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260921/27085572.html

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Mon, 21 Sep 2026 16:15:00 -0400

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth
Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision
Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Mon, 21 Sep 2026 16:15:00 -0400
- Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth
- Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision
- Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027
  
  Form 4 ANAPTYSBIO, INC For: Sep 15 Filed by: Orwin John A
  
  Thu, 17 Sep 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260917/27075828.html
  
  Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
  
  Tue, 01 Sep 2026 16:15:00 -0400
  
  SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.
  
  A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30
  
  Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
  
  Tue, 01 Sep 2026 16:15:00 -0400
  
  SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.
  
  A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30
  
  Wolfe Research Reiterates Outperform Rating on AnaptysBio (ANAB)
  
  Mon, 31 Aug 2026 05:37:37 -0400
  
  Wolfe Research analyst Andy Chen reiterated an Outperform rating and $78.00 price target on AnaptysBio (NASDAQ: ANAB).
  The analyst comments "The contractual language of the amendment between Anaptys and Tesaro/GSK is convoluted, with different phrases supporting each side’s interpretation. GSK can point to language broadly exempting GSK and its affiliates from exclusivity, while Anaptys can point to provisions expressly prohibiting Tesaro from transferring or licensing Jemperli to GSK and preserving Tesaro’s CRE obligations. Based on our interpretation, the contractual language on freedom to operate is not the tiebreaker (because it is ambiguous), but evidence around it. More importantly, Anaptys needs only
  
  AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen
  
  Tue, 25 Aug 2026 07:37:29 -0400
  
  TD Cowen analyst Joseph Thome lowered the price target on AnaptysBio (NASDAQ: ANAB) to $70.00 (from $75.00) while maintaining a Buy rating.
  The analyst commented: "GSK announced the FDA accepted Jemperli's sBLA for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer, assigning a February 2027 PDUFA. The application is also eligible for CNPV review and Project Orbis, which could support an earlier decision. We model ~$290MM in peak U.S. sales for the indication."
  
  AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen
  
  Tue, 25 Aug 2026 07:37:29 -0400
  
  TD Cowen analyst Joseph Thome lowered the price target on AnaptysBio (NASDAQ: ANAB) to $70.00 (from $75.00) while maintaining a Buy rating.
  The analyst commented: "GSK announced the FDA accepted Jemperli's sBLA for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer, assigning a February 2027 PDUFA. The application is also eligible for CNPV review and Project Orbis, which could support an earlier decision. We model ~$290MM in peak U.S. sales for the indication."
  
  Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP
  
  Fri, 14 Aug 2026 08:31:00 -0400
  si-local-file:///var/storage/secattach/20260814/26925175.html
  
  Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP
  
  Fri, 14 Aug 2026 08:31:00 -0400
  si-local-file:///var/storage/secattach/20260814/26925175.html
  
  Form 8-K ANAPTYSBIO, INC For: Aug 11
  
  Tue, 11 Aug 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260811/26905592.html
  
  Form 8-K ANAPTYSBIO, INC For: Aug 11
  
  Tue, 11 Aug 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260811/26905592.html
  
  Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.
  
  Fri, 07 Aug 2026 17:13:00 -0400
  si-local-file:///var/storage/secattach/20260807/26892180.html
  
  Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.
  
  Fri, 07 Aug 2026 17:13:00 -0400
  si-local-file:///var/storage/secattach/20260807/26892180.html
  
  Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel
  
  Fri, 07 Aug 2026 17:12:00 -0400
  si-local-file:///var/storage/secattach/20260807/26892173.html
  
  Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel
  
  Fri, 07 Aug 2026 17:12:00 -0400
  si-local-file:///var/storage/secattach/20260807/26892173.html
  
  Form 8-K ANAPTYSBIO, INC For: Jul 28
  
  Thu, 30 Jul 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260730/26843511.html
  
  Form 8-K ANAPTYSBIO, INC For: Jul 28
  
  Thu, 30 Jul 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260730/26843511.html

StreetInsider.com News Articles

Form 4 ANAPTYSBIO, INC For: Oct 01 Filed by: RENTON HOLLINGS

Form 144 ANAPTYSBIO, INC Filed by: RENTON HOLLINGS

AnaptysBio (ANAB) PT Lowered to $60 at JPMorgan

AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c

H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)

Form 10-KT ANAPTYSBIO, INC For: Jun 30

Form 8-K ANAPTYSBIO, INC For: Sep 21

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Form 4 ANAPTYSBIO, INC For: Sep 15 Filed by: Orwin John A

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

Wolfe Research Reiterates Outperform Rating on AnaptysBio (ANAB)

AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen

AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen

Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP

Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP

Form 8-K ANAPTYSBIO, INC For: Aug 11

Form 8-K ANAPTYSBIO, INC For: Aug 11

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel

Form 8-K ANAPTYSBIO, INC For: Jul 28

Form 8-K ANAPTYSBIO, INC For: Jul 28